Taipei-based biotech company Jyong Biotech Ltd. has leveraged a successful IPO to accelerate the development of MCS-2, a promising treatment for benign prostatic hyperplasia (BPH).
Syrian soldiers make their way through the snow in the country’s mountainous Qalamoun region,near the border with Lebanon,during a patrol to secure the frontier (Picture: AFP)
